Hanwha Of S. Korea To Invest Heavy In Biotech Industry
This article was originally published in PharmAsia News
Executive Summary
South Korea's Hanwha Group is betting on the country's biotechnology industry as the next new area of growth. The conglomerate said its Hanwha Chemical and Dream Pharma units are set to collaborate for a major presence in the market for therapeutic antibodies. Hanwha's bio division has been working on the antibodies for the past two years and is ready to bring one of them to human clinical trials. Hanwha is investing just over $22 million in a large-scale production center. (Click here for more
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.